CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Significant prevalence of fibromyalgia among the population
3.4.1.2. Surge in awareness regarding fibromyalgia and its treatment
3.4.1.3. Enhanced access to generic medications for fibromyalgia treatment
3.4.2. Restraints
3.4.2.1. Availability of alternate treatment options
3.4.2.2. Lack of awareness about fibromyalgia in underdeveloped countries
3.4.3. Opportunities
3.4.3.1. Robust pipeline of products for fibromyalgia treatment
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Antidepressants
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Anticonvulsants
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Muscle Relaxants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Drug stores and retail pharmacies
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Online providers
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: FIBROMYALGIA TREATMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Drug Class
6.2.3. Market size and forecast, by Distribution Channel
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Drug Class
6.2.4.1.3. Market size and forecast, by Distribution Channel
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Drug Class
6.2.4.2.3. Market size and forecast, by Distribution Channel
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Drug Class
6.2.4.3.3. Market size and forecast, by Distribution Channel
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Drug Class
6.3.3. Market size and forecast, by Distribution Channel
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Drug Class
6.3.4.1.3. Market size and forecast, by Distribution Channel
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Drug Class
6.3.4.2.3. Market size and forecast, by Distribution Channel
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Drug Class
6.3.4.3.3. Market size and forecast, by Distribution Channel
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Drug Class
6.3.4.4.3. Market size and forecast, by Distribution Channel
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Drug Class
6.3.4.5.3. Market size and forecast, by Distribution Channel
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Drug Class
6.3.4.6.3. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Drug Class
6.4.3. Market size and forecast, by Distribution Channel
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Drug Class
6.4.4.1.3. Market size and forecast, by Distribution Channel
6.4.4.2. China
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Drug Class
6.4.4.2.3. Market size and forecast, by Distribution Channel
6.4.4.3. India
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Drug Class
6.4.4.3.3. Market size and forecast, by Distribution Channel
6.4.4.4. Australia
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Drug Class
6.4.4.4.3. Market size and forecast, by Distribution Channel
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Drug Class
6.4.4.5.3. Market size and forecast, by Distribution Channel
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Drug Class
6.4.4.6.3. Market size and forecast, by Distribution Channel
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Drug Class
6.5.3. Market size and forecast, by Distribution Channel
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Drug Class
6.5.4.1.3. Market size and forecast, by Distribution Channel
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Drug Class
6.5.4.2.3. Market size and forecast, by Distribution Channel
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Drug Class
6.5.4.3.3. Market size and forecast, by Distribution Channel
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Drug Class
6.5.4.4.3. Market size and forecast, by Distribution Channel
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. Amneal Pharmaceuticals LLC
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Eli Lilly and Company
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Lupin Limited.
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Novartis AG
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Viatris Inc.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. Zydus Lifesciences Limited
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Sun Pharmaceutical Industries Limited
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. AbbVie Inc.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
TABLE 01. GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. FIBROMYALGIA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. FIBROMYALGIA TREATMENT MARKET FOR ANTICONVULSANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. FIBROMYALGIA TREATMENT MARKET FOR MUSCLE RELAXANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. FIBROMYALGIA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 07. FIBROMYALGIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 08. FIBROMYALGIA TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. FIBROMYALGIA TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. FIBROMYALGIA TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 11. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 14. U.S. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 15. U.S. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. CANADA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 17. CANADA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 18. MEXICO FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 19. MEXICO FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 20. EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 21. EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 22. EUROPE FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 23. GERMANY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 24. GERMANY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. FRANCE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 26. FRANCE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. UK FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 28. UK FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. ITALY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 30. ITALY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. SPAIN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 32. SPAIN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 34. REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 36. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 38. JAPAN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 39. JAPAN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. CHINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 41. CHINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. INDIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 43. INDIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. AUSTRALIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 45. AUSTRALIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. SOUTH KOREA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 47. SOUTH KOREA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. LAMEA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 51. LAMEA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. LAMEA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 54. BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 56. SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 58. SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. REST OF LAMEA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 60. REST OF LAMEA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 62. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 63. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 64. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 65. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 66. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 67. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
TABLE 68. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 69. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES
TABLE 70. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 71. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 72. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 73. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 74. LUPIN LIMITED.: KEY EXECUTIVES
TABLE 75. LUPIN LIMITED.: COMPANY SNAPSHOT
TABLE 76. LUPIN LIMITED.: PRODUCT SEGMENTS
TABLE 77. LUPIN LIMITED.: PRODUCT PORTFOLIO
TABLE 78. LUPIN LIMITED.: KEY STRATERGIES
TABLE 79. NOVARTIS AG: KEY EXECUTIVES
TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 81. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 83. NOVARTIS AG: KEY STRATERGIES
TABLE 84. VIATRIS INC.: KEY EXECUTIVES
TABLE 85. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 86. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 87. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 88. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 89. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 90. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 91. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 92. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
TABLE 93. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 94. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 95. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 96. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 101. ABBVIE INC.: KEY EXECUTIVES
TABLE 102. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 103. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 104. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 105. ABBVIE INC.: KEY STRATERGIES
